Yahoo España Búsqueda web

Entrar

Search results

  1. stockanalysis.com › stocks › praxPraxis Precision Medicines, Inc. (PRAX) - Stock Analysis

    Hace 4 días · Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.

  2. seekingalpha.com › symbol › PRAXPraxis Precision Medicines, Inc. (PRAX) Stock Price, Quote, News...

    1 de jul. de 2024 · Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation...

  3. simplywall.st › stocks › usPraxis Precision Medicines (Nasdaq:PRAX) - Simply Wall St

    Hace 4 días · Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.

  4. www.cnn.com › markets › stocksPRAX Stock Quote Price and Forecast | CNN

    1 de jul. de 2024 · Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS,...

  5. Vídeos

    Ver todo

  6. www.bloomberg.com › quote › PRAX:USPRAX: Praxis Precision Medicines Inc Stock Price Quote -...

    Hace 4 días · Stock analysis for Praxis Precision Medicines Inc (PRAX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

  7. www.marketbeat.com › stocks › NASDAQPraxis Precision Medicines (PRAX) Stock Price, News & Analysis -...

    Hace 3 días · Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.

  8. synapse.patsnap.com › drug › 5c85a9e04d8c40a99968584ad7c7268bPX-070101 - Drug Targets, Indications, Patents - Synapse

    19 de jun. de 2024 · PX-070101: a EGFR agonists Drug, Initially developed by Praxis Pharmaceutical SA, Now, its global highest R&D status is Approved, Mechanism: EGFR agonists(Epidermal growth factor receptor erbB1 agonists), Therapeutic Areas: Nervous System Diseases,Cardiovascular Diseases,Endocrinology and Metabolic Disease, Active Indication ...